New antivirals - mechanism of action and resistance development

被引：42

作者：

Balzarini, J ^{[1
]}

Naesens, L ^{[1
]}

De Clercq, E ^{[1
]}

机构：

[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

来源：

CURRENT OPINION IN MICROBIOLOGY | 1998年 / 1卷 / 05期

关键词：

D O I：

10.1016/S1369-5274(98)80086-6

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

In recent years, several novel treatment modalities emerged for a number of virus infections, including lamivudine for hepatitis B virus, abacavir, adefovir dipivoxyl and apropovir disprometil for human immunodeficiency virus, cidofovir for cytomegalovirus, and famciclovir (the oral prodrug of penciclovir) and cidofovir for other herpesviruses (i.e. herpes simplex virus and varicella-zoster virus). For all drugs, resistance eventually develops upon prolonged administration to the infected individuals, albeit to a varying extent. In addition, new mutations related to multidrug resistance have recently been identified.

引用

页码：535 / 546

页数：12

共 73 条

[1] Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation [J].

Aye, TT ;

Bartholomeusz, A ;

Shaw, T ;

Bowden, S ;

Breschkin, A ;

McMillan, J ;

Angus, P ;

Locarnini, S .

JOURNAL OF HEPATOLOGY, 1997, 26 (05) :1148-1153

[2] Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS [J].

Baldanti, F ;

Underwood, MR ;

Stanat, SC ;

Biron, KK ;

Chou, SW ;

Sarasini, A ;

Silini, E ;

Gerna, G .

JOURNAL OF VIROLOGY, 1996, 70 (03) :1390-1395

[3]

Baldanti F, 1998, ANTIMICROB AGENTS CH, V42, P444

[4] MARKED INVIVO ANTIRETROVIRUS ACTIVITY OF 9-(2-PHOSPHONYLMETHOXY-ETHYL)ADENINE, A SELECTIVE ANTI-HUMAN IMMUNODEFICIENCY VIRUS AGENT [J].

BALZARINI, J ;

NAESENS, L ;

HERDEWIJN, P ;

ROSENBERG, I ;

HOLY, A ;

PAUWELS, R ;

BABA, M ;

JOHNS, DG ;

DECLERCQ, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (01) :332-336

[5] INTRACELLULAR METABOLISM AND MECHANISM OF ANTIRETROVIRUS ACTION OF 9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE, A POTENT ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS COMPOUND [J].

BALZARINI, J ;

ZHANG, H ;

HERDEWIJN, P ;

JOHNS, DG ;

DECLERCQ, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (04) :1499-1503

[6] DIFFERENTIAL ANTIHERPESVIRUS AND ANTIRETROVIRUS EFFECTS OF THE (S) AND (R) ENANTIOMERS OF ACYCLIC NUCLEOSIDE PHOSPHONATES - POTENT AND SELECTIVE INVITRO AND INVIVO ANTIRETROVIRUS ACTIVITIES OF (R)-9-(2-PHOSPHONOMETHOXYPROPYL)-2,6-DIAMINOPURINE [J].

BALZARINI, J ;

HOLY, A ;

JINDRICH, J ;

NAESENS, L ;

SNOECK, R ;

SCHOLS, D ;

DECLERCQ, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (02) :332-338

[7]

BALZARINI J, IN PRESS BIOCH PHARM

[8] Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [J].

Bartholomew, MM ;

Jansen, RW ;

Jeffers, LJ ;

Reddy, KR ;

Johnson, LC ;

Bunzendahl, H ;

Condreay, LD ;

Tzakis, AG ;

Schiff, ER ;

Brown, NA .

LANCET, 1997, 349 (9044) :20-22

[9] EFFICACY OF LAMIVUDINE ON REPLICATION OF HEPATITIS-B VIRUS IN HIV-INFECTED PATIENTS [J].

BENHAMOU, Y ;

DOHIN, E ;

LUNELFABIANI, F ;

POYNARD, T ;

HURAUX, JM ;

KATLAMA, C ;

OPOLON, P ;

GENTILINI, M .

LANCET, 1995, 345 (8946) :396-397

[10]

Bowen EF, 1997, J VIROL METHODS, V68, P225

← 1 2 3 4 5 6 7 8 →